Therapeutic plasma exchange in Casablanca

Therapeutic plasma exchange is used to remove harmful proteins from blood in various diseases. Prior research has shown its effectiveness in neurological and autoimmune conditions. However, data from individual centers remain limited in some regions. This gap motivated a review of local TPE practices in Casablanca. No prior work had resolved the extent of TPE use in this area. The study aimed to address this uncertainty by analyzing procedures and outcomes. Neurological departments have long been key users of TPE. Yet, the specific patterns of use in this setting were not well documented. This paper contributes by providing a detailed summary of local TPE activity.

The study aimed to evaluate the use of therapeutic plasma exchange at a single center in Casablanca. It focused on patient demographics, indications, and outcomes of TPE procedures. The motivation was to document local practice and identify areas for improvement. Neurological conditions were the primary focus due to their high prevalence in TPE use. The researchers also wanted to assess the safety and efficacy of procedures. They examined patient responses and adverse events to guide future practice. The goal was to inform the development of a national registry for TPE. This would help standardize treatment and improve patient outcomes.

The study analyzed TPE procedures performed between 2002 and 2005 at a single center. Data were collected on patient age, gender, and referring departments. Indications for TPE were categorized by disease type. Vascular access was typically achieved via peripheral vein puncture. The Haemonetic Ultralight device was used for all procedures. Citrate solution served as the anticoagulant in every case. Substitution fluids included albumin and fresh frozen plasma. Patient outcomes were tracked to assess improvement and adverse events.

A total of 104 TPE procedures were performed on 42 patients over three years. The median age of patients was 32, with a male-to-female ratio of 24 to 18. Neurology referred the most patients, followed by nephrology and ICU. Polyradiculoneuropathies were the most common indication at 53%. Myasthenia gravis and Guillain-Barré syndrome followed at 17% and 12%. The average number of procedures per patient was 2.3. Albumin 20% was used in 92 cases, with fewer uses of other fluids. Seventy-five percent of patients improved, while 18% worsened.

The study highlights the use of TPE in neurological and autoimmune conditions in Casablanca. Neurology was the leading department for TPE referrals. Polyradiculoneuropathies were the most frequent indication. Albumin 20% was the most common substitution fluid. Most patients showed improvement, though a notable minority worsened. Thirteen adverse events were recorded, indicating a need for caution. The authors propose that a national registry would standardize TPE practices. They suggest this could improve patient outcomes and procedural safety.